Navigation Links
Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
Date:5/7/2012

TARRYTOWN, N.Y., May 8, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare today announced that Bayer's Japanese subsidiary, Bayer Yakuhin, Ltd. ("Bayer Yakuhin"), and Santen Pharmaceutical Co., Ltd.("Santen")entered into a co-promotion agreement for EYLEA® (aflibercept) Injection in Japan.  As previously announced, Bayer Yakuhin has submitted an application for marketing authorization to the Ministry of Health, Labor and Welfare (MHLW) for EYLEA for the treatment of neovascular age-related macular degeneration (wet AMD).

"With this agreement and upon marketing authorization, a newly formed Bayer Yakuhin ophthalmology field force and Santen, the leading ophthalmology company in Japan, will promote EYLEA," said Sebastian Guth, President & CEO of Bayer Yakuhin, Ltd.  "We expect that the combined resources of the two companies will allow EYLEA to achieve a broader and faster reach into the Japanese ophthalmology community and potentially benefit a greater number of patients."

Bayer and Regeneron have also amended their existing global license and collaboration agreement for EYLEA to convert the 50/50 profit share for Japan into a royalty arrangement that approximates the economics of the profit split.  In certain specified circumstances, the royalty may revert to a profit share arrangement.

EYLEA is approved for sale in the United States for the treatment of wet AMD and marketing approval has also been granted in Australia.  Bayer HealthCare has submitted applications in Europe and other countries and has initiated a Phase 3 clinical study for wet AMD in China. Beyond the wet AMD indication, EYLEA is in Phase 3 clinical studies for the treatment of diabetic macular edema (DME), myopic choroidal neovascularization (mCNV), and branch retinal vein occlusion (BRVO).  Regeneron
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Regeneron to Report First Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on April 26, 2012
2. Regeneron Announces Data Publication and Presentations with Potential First-in-Class Lipid-Lowering PCSK9 Antibody
3. Regeneron Announces February 2012 Investor Conference Presentations
4. Regeneron to Report Full Year 2011 Financial and Operating Results and Host Conference Call and Webcast on February 16, 2012
5. Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
6. Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
7. Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
8. Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
9. Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
10. Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
11. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 2015   Mallinckrodt Pharmaceuticals (NYSE: MNK ... it has extended the deadline for submitting applications to ... The program awards grants to help fund projects in ... Research Fellowship Awards program is designed to further scientific ... will award a total of 25 positions. The program ...
(Date:5/26/2015)... 2015  Over the past several years, numerous studies ... a sleeve gastrectomy, and weight loss surgery in ... recently, a study conducted by Italian researchers and published ... that obese patients suffering from an overactive bladder tend ... losing weight with a laparoscopic sleeve gastrectomy. This is ...
(Date:5/26/2015)... -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ) ("the Company"), ... that address unmet medical needs in women,s health, ... will present at the Marcum MicroCap Conference as ... PM EDTLocation: , The Grand Hyatt, New York, ... ,Investor, or  click here The webcast ...
Breaking Medicine Technology:Mallinckrodt Extends Deadline For 2015 Research Fellowship Program 2Mallinckrodt Extends Deadline For 2015 Research Fellowship Program 3Add Overactive Bladder Syndrome to the List of Conditions Shown to Be Improved by a Sleeve Gastrectomy 2Juniper Pharmaceuticals to Present at Investor Conference on May 28, 2015 2
... ROSA, Calif., March 12 Northern California Foot,and ... recruiting patients with,lower extremity diabetic foot ulcers to ... trial will study the effects of Excellarate(TM),(GAM501) (Ad5PDGF-B/bovine ... patients with neuropathic non-healing diabetic foot ulcers. Excellarate,is ...
... with Education & ... ... Journal of,the American Medical Association on the largest weight loss maintenance,study ... both personal contact and web-based support are,identified as the key to ...
Cached Medicine Technology:Northern California Foot and Ankle Center Santa Rosa Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Research Trial 2Study Finds Personal and Web-Based Support Equal Weight Loss Success 2Study Finds Personal and Web-Based Support Equal Weight Loss Success 3Study Finds Personal and Web-Based Support Equal Weight Loss Success 4
(Date:5/26/2015)... Allprovide, the all-natural raw pet food company, ... are now available in three Georgia stores: Pooch-n-Paws in ... Old Dog Company in Kennesaw. , Allprovide is based ... state-of-the-art, climate controlled facility. The fresh ingredients come from ... the food is triple-tested for quality. Unlike most pet ...
(Date:5/26/2015)... May 26, 2015 Pasadena porcelain ... complimentary dental cleanings with cosmetic treatments. Cosmetic dentistry is ... Cosmetic Dentistry , “We are committed to providing you ... technology, outstanding customer service and a smile of a ... change your smiles but to change your life,” explains ...
(Date:5/26/2015)... May 26, 2015 Hexagon Geospatial is ... Defence and Space in a new content-sharing program that ... for use in the development of smart applications. ... this partnership combines optical satellite data from Airbus Defence ... tear down the walls between geospatial content, software and ...
(Date:5/26/2015)... Rosa, CA (PRWEB) May 26, 2015 ... and Analytics solutions for more than 15 years, has ... the National Committee for Quality Assurance (NCQA) for its ... , “We are proud of the work we have ... and are grateful for the acknowledgement from NCQA once ...
(Date:5/26/2015)... Scientists at the University of Pennsylvania ... advanced mesothelioma patients benefit from immunotherapy; surgery may be ... on the new research. Click here to read ... thoracic surgery and pulmonology theorized that, because large mesothelioma ... attack, immunotherapy drugs might work better if the tumor ...
Breaking Medicine News(10 mins):Health News:Allprovide, the All-Natural Pet Food, Available At Georgia Retailers 2Health News:Pasadena Porcelain Veneers Expert, Marine Martirosyan DDS, is Now Offering Complimentary Dental Cleaning with Cosmetic Treatments 2Health News:Hexagon Geospatial and Airbus Defense Establish Partnership 2Health News:Hexagon Geospatial and Airbus Defense Establish Partnership 3Health News:i2iTracks Earns NCQA 2014 PCMH Prevalidation 2Health News:i2iTracks Earns NCQA 2014 PCMH Prevalidation 3Health News:Researchers Say Surgery May Restore Effectiveness of Immunotherapy for Mesothelioma, According to Surviving Mesothelioma 2
... latest study researchers say health professionals and patients require ... associated with over the counter drugs. Of the many ... most common condition that people choose to treat by ... commonly treated ailments include heartburn, migraine, period pain, coughs, ...
... started with a big bang, bringing hope and aspirations for people// ... own. 2001 opened with it Pandora ’s Box of ... first internationally reported disaster was in 2000 on February 1st in ... Soon after a whole string of disasters followed. ,Droughts ...
... a group of genes known as a gene signature, that ... at high risk for having a future cancer recurrence .// ... tumor samples from 209 lymph-node-negative breast cancer patients were examined. ... initial cancer treatment and varied in age and in their ...
... skin cancer – melanoma ,however researchers as the number of ... of patients surviving the disease. // Two new studies show ... of cancer. In a study conducted by researchers on patients ... was discovered that melanoma patients with higher levels of sun ...
... discovery could help prevent complications for pregnant women with ... after the 20th week of pregnancy and is characterized ... in the urine. In severe cases it can lead ... causes the mother to suffer a series of potentially ...
... study, advanced imaging techniques reveals unexpected structural differences in ... compared detailed images of the brain structure // of ... from 27 healthy patients. ,Results showed the amygdala ... research has linked to the brain's reward processing system ...
Cached Medicine News:Health News:SARS (Bird Flu) spreading in the Asian continent 2
Prevents contamination of RNA experiments commonly caused by latex gloves; made of Nitrile; these gloves are also certified free of Dnase...
These handy dispensers save space and organize gloves in labs and next to hand washers. Clear acrylic. Many other sizes and custom configurations available....
... 8000 retracting base sliding microtome offers the ... reliability and, not least, safety. ,Designed to ... laboratory, the 8000 will also meet the ... where its versatility and wide range of ...
... Leica VT1000 S is a vibrating blade ... to meet the highly sophisticated sectioning requirements ... neurophysiology, neuropathology and experimental (brain) research ... and some industrial applications related to structural ...
Medicine Products: